Research Analysts Issue Forecasts for Corcept Therapeutics Incorporated’s Q1 2026 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research cut their Q1 2026 EPS estimates for Corcept Therapeutics in a note issued to investors on Tuesday, October 1st. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.45 for the quarter, down from their previous estimate of $0.46. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.51 EPS and Q3 2026 earnings at $0.57 EPS.

CORT has been the subject of several other reports. Piper Sandler lifted their price target on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a research report on Tuesday, July 30th. Truist Financial raised their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a report on Monday, September 30th. Finally, HC Wainwright upped their price objective on shares of Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $56.50.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $45.43 on Friday. Corcept Therapeutics has a one year low of $20.84 and a one year high of $47.71. The business’s 50-day moving average price is $37.50 and its two-hundred day moving average price is $31.49. The company has a market capitalization of $4.73 billion, a P/E ratio of 42.86 and a beta of 0.46.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.23 by $0.09. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The business had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $155.14 million. During the same period in the previous year, the company posted $0.25 EPS. Corcept Therapeutics’s revenue was up 39.1% on a year-over-year basis.

Institutional Trading of Corcept Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in shares of Corcept Therapeutics by 90.6% during the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 579 shares during the last quarter. Park Place Capital Corp acquired a new position in Corcept Therapeutics in the 2nd quarter valued at approximately $32,000. Atwood & Palmer Inc. bought a new stake in shares of Corcept Therapeutics in the 2nd quarter worth approximately $35,000. FinTrust Capital Advisors LLC grew its holdings in shares of Corcept Therapeutics by 318.7% during the 1st quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,348 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Corcept Therapeutics by 125.4% during the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,962 shares during the period. 93.61% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total transaction of $509,080.00. Following the completion of the sale, the insider now directly owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider William Guyer sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total value of $353,000.00. Following the completion of the sale, the insider now directly owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total transaction of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at $1,053,888.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,251 shares of company stock valued at $1,365,292 over the last 90 days. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.